Skip to main content
SpringerLink
Log in

Correction of physiological alterations of hypertension

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frohlich ED. Haemodynamics of hypertension. In: Genest J, Koiw E, Kuchel O, eds.Hypertension: Physiopathology and treatment. New York: McGraw-Hill Book Company, 1977. pp. 15–49.

    Google Scholar 

  2. Frohlich ED. Hemodynamic factors in the pathogenesis and maintenance of hypertension.Fed Proceed 1982;41:2400–2408.

    Google Scholar 

  3. Frohlich ED. The heart in hypertension. In: Genest J, Kuchel O, Hamet P, et al. eds.Hypertension: Physiopathology and treatment, 2nd ed. New York: McGraw-Hill Book Company, 1983. pp. 791–810.

    Google Scholar 

  4. Frohlich ED. Hemodynamics and other determinants in development of left ventricular hypertrophy: Conflicting factors in its regression.Fed Proceed 1983;42:2709–2715.

    Google Scholar 

  5. Leitschuh M, Chobanian A. Vascular changes in hypertension.Medical Clinics of North America (in press).

  6. Folkow B. Physiological aspects of primary hypertension.Physiol Reviews 1982;62:347–504.

    Google Scholar 

  7. Frohlich ED. Newer antihypertensive drugs. In: Yu PN, Goodwin JF, eds.Progress in Cardiology, Vol. 12. Philadelphia: Lea & Febiger, 1984. pp. 265–281.

    Google Scholar 

  8. Frohlich ED. Antihypertensive therapy: Newer concepts and agents.Cardiology 1985;72:349–365.

    PubMed  Google Scholar 

  9. Frohlich ED. Changes in hypertrophy by treatment in hypertension: Results of experimental research. In: Kaufman W. Bonner G, Lang I, et al. eds.Primary hypertension. Berlin/Heidelberg: Springer-Verlag, 1986. pp. 105–114.

    Google Scholar 

  10. Frohlich ED. Potential mechanisms explaining the risk of left ventricular hypertrophy.Am J Cardiol 1987;59:91A-97A.

    PubMed  Google Scholar 

  11. Frohlich ED. The heart in hypertension. In: Rosenthal J, Chobanian AV, eds.Arterial hypertension, 2nd ed. Springer-Verlag (in press).

  12. Frohlich ED, Tarazi RC: Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy?Am J Cardiol 1979;44:959–963.

    PubMed  Google Scholar 

  13. Tarazi RC, Frohlich ED. Is reversal of cardiac hypertrophy a desirable goal of antihypertensive therapy?Circulation 1987;75:I113-I117.

    PubMed  Google Scholar 

  14. Weil JV, Chidsey CA. Plasma volume expansion resulting from interference with adrenergic function in normal man.Circulation 1968;37:54–61.

    PubMed  Google Scholar 

  15. Dustan HP, Tarazi RC, Bravo EL. Dependence of arterial pressure on intravascular volume in treated hypertensive patients.N Engl J Med 1972;286:861–866.

    PubMed  Google Scholar 

  16. Perry HM (Chairman). Recommendations for a national high blood pressure program data base for effective antihypertensive therapy. Report of Task Force I, DHEW Publication No. (NIH) 75-593, US Dept of Health, Education and Welfare, Bethesda, MD, 1973.

    Google Scholar 

  17. Frohlich ED. Diuretics: State of the art.J Hypertension (in press).

  18. Tarazi RC, Frohlich ED, Dustan HP. Plasma volume changes with long-term beta-adrenergic blockade.Am Heart J 1971;82:770–776.

    PubMed  Google Scholar 

  19. Dreslinski GR, Messerli FH, Dunn FG, et al. Hemodynamics, biochemical and reflexive changes produced by atenolol in hypertension.Circulation 1982;65:1365–1368.

    PubMed  Google Scholar 

  20. Ventura HO, Frohlich ED, Messerli FH, et al. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension.Am J Cardiol 1985;55:1023–1026.

    PubMed  Google Scholar 

  21. Dunn FG, Oigman W. Ventura HO, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension.Am J Cardiol 1984;53:105–108.

    PubMed  Google Scholar 

  22. Amodeo C, Kobrin I, Ventura HO, et al. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension.Circulation 1986;73:108–113.

    PubMed  Google Scholar 

  23. Frohlich ED, Messerli FH, Dreslinski GR, et al. Long-term renal hemodynamic effects of nadolol in patients with essential hypertension.Am Heart J 1984;108:1141–1143.

    PubMed  Google Scholar 

  24. Fleckenstein A. History of calcium antagonists.Circ Res 1983;51:I3-I16.

    Google Scholar 

  25. Vaghy PL, Williams JS, Schwartz A. Receptor pharmacology of calcium entry blocking agents.Am J Cardiol 1987;59:9A-17A.

    PubMed  Google Scholar 

  26. Bevan JA, Bevan RD, Hwa JJ, et al. Calcium regulation invascular smooth muscle: Is there a pattern to its variability within the arterial tree?J Cardiovasc Pharmacol 1986;8(Suppl 8):571–575.

    Google Scholar 

  27. Olivari MT, Bartorelli C, Polese A, et al. Treatment of hypertension with nifedipine: A calcium antagonist agent.Circulation 1979;59:1056–1062.

    PubMed  Google Scholar 

  28. Lund-Johansen P. Hemodynamic long-term effects of verapamil in essential hypertension at rest and during exercise.Acta Med Scand 1984;Suppl 681:109–115.

    Google Scholar 

  29. Natsume T, Kardon MB, Pegram BL, et al. Ventricular performance in SHR with regressed cardiac hypertrophy. (Submitted)

  30. Pegram BL, Frohlich ED. Immediate systemic and regional hemodynamic effects of MK-421 converting enzyme inhibitor in conscious Wistar-Kyoto and spontaneously hypertensive rats. In: Rascher W, Clough D, Ganten D, eds.Hypertensive mechanisms of the spontaneously hypertensive rat as a model to study human hypertension. New York and Stuttgart: F K Schattauer, 1982. pp. 677–680.

    Google Scholar 

  31. Natsume T, Gallo A, Pegram BL, et al. Hemodynamic effects of prolonged treatment with diltiazem in conscious normotensive and spontaneously hypertensive rats.Clin Exper Hyper 1985;A7:1471–1479.

    Google Scholar 

  32. Kobrin I, Sesoko S, Pegram BL, et al. Reduced cardiac mass by nitrendipine is dissociated from systemic or regional haemodynamic changes in rats.Cardiovasc Res 1984;3:158–162.

    Google Scholar 

  33. Garavaglia GE, Nunez BD, Messerli FH, et al. Systemic and regional hemodynamic effects of nitrendipine in patients with essential hypertension. (Submitted)

  34. Loutzenheiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics. An editorial review.Am J Physiol 1985;249:F619-F629.

    PubMed  Google Scholar 

  35. Isshiki T, Amodeo C, Messerli FH, Pegram BL, Frohlich ED. Diltiazem maintains renal vasodilation without hyperfiltration in hypertension: Studies in essential hypertensive man and the spontaneously hypertensive rat.Cardiovascular Drugs and Therapy (this issue).

  36. Ventura HO, Messerli FH, Oigman W, et al. Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension.Am J Cardiol 1983;51:783–786.

    PubMed  Google Scholar 

  37. Pedrinelli R, Fouad FM, Tarazi RC, et al. Nitrendipine, a calcium-entry blocker. Renal and humoral effects in human arterial hypertension.Arch Intern Med 1986;146:62–65.

    PubMed  Google Scholar 

  38. Bauer JH. Renal protective effects of calcium antagonists.Cardiovascular Drugs and Therapy (this issue).

  39. Schmieder RE, Messerli FH, Garavaglia GE, et al. Cardiovascular effects of verapamil in essential hypertension.Circulation (in press).

  40. Gomez DM. Evaluation of renal resistances with special reference to changes in essential hypertension.J Clin Invest 1951;30:1143–1155.

    PubMed  Google Scholar 

  41. Kobrin I, Pegram BL, Frohlich ED. Acute pressure increase and intrarenal hemodynamics in conscious WKY and SHR rats.Am J Physiol 1985;18:H1114-H1118.

    Google Scholar 

  42. Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat.Circ Res 1975;37:101–110.

    PubMed  Google Scholar 

  43. Hostetter TH, Olson JL, Rennke HG, et al. Hyperfiltration in remnant nephrons: A potentially adverse response to renal ablation.Am J Physiol 1981;241:F85-F93.

    PubMed  Google Scholar 

  44. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.Am J Med 1982;72 375–380.

    PubMed  Google Scholar 

  45. Zusman RM. Renin and non-renin-mediated antihypertensive action of converting enzyme inhibitors.Kidney Int 1984;25:969–983.

    PubMed  Google Scholar 

  46. Navar LG, Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics.Kidney Int 1984;25:857–868.

    PubMed  Google Scholar 

  47. Anderson S, Meyer TW, Rennke HG, et al. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.J Clin Invest 1985;76:612–619.

    PubMed  Google Scholar 

  48. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal diseases associated with systemic hypertension in the rat.J Clin Invest 1986;77:1993–2000.

    PubMed  Google Scholar 

  49. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction.Arch Intern Med 1986;146:2145–2148.

    PubMed  Google Scholar 

  50. Tagama Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetic patients.N Engl J Med 1985;313:1617–1620.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alton Ochsner Medical Foundation, 1516 Jefferson Highway, 70121, New Orleans, Louisiana, USA

    Edward D. Frohlich (Vice President for Academic Affairs)

Authors
  1. Edward D. Frohlich
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frohlich, E.D. Correction of physiological alterations of hypertension. Cardiovasc Drug Ther 1, 345–348 (1987). https://doi.org/10.1007/BF02209074

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02209074

Key words

Search

Navigation